Thomas Garner Joins Acadia As Chief Commercial Officer

Acadia Pharmaceuticals Inc. has announced the appointment of Thomas Andrew Garner as Chief Commercial Officer, effective immediately. Mr. Garner will oversee Acadia's commercial strategy and operations in this role. It will focus on the company’s product portfolio, pipeline growth, and expansion across U.S. and international markets. Reporting to CEO Catherine Owen Adams, he will also join Acadia’s executive leadership team.

Mr. Garner brings over 25 years of commercial experience in the pharmaceutical industry, including sales, marketing, medical affairs, pricing, and business development expertise. Most recently, he served as Chief Commercial Officer at Lexicon Pharmaceuticals, Inc., where he led the relaunch of INPEFA (sotagliflozin) and developed strategies for the company’s broader product portfolio. Before that, he spent over two decades at Bristol Myers Squibb (BMS) and held senior leadership roles. 

As Senior Vice President and head of BMS’s U.S. Cardiovascular and Established Brands business unit, he managed a portfolio generating more than $10 billion in annual revenue, including leading brands like ELIQUIS® (apixaban) and CAMZYOS® (mavacamten). Earlier in his career, he successfully launched primary cancer therapies such as OPDIVO® (nivolumab) and YERVOY® (ipilimumab) globally.

Catherine Owen Adams, CEO, said in a statement, “Tom is an accomplished commercial executive with a demonstrated history of driving brand growth across therapeutic areas and global businesses. His experience includes many successful brand launches, including those in neuropsychiatric and rare cardiac diseases. We are thrilled to welcome him into this pivotal commercial leadership role as we continue our launch of DAYBUE™ in the US while also preparing for launches outside the U.S. and building a strong foundation for the potential introduction of new therapies in the future.”

Mr Garner’s international experience includes serving as General Manager for BMS Denmark and holding roles at Boehringer Ingelheim and Eli Lilly in the UK. He holds a BSc (Honors) from the Royal Agricultural University and a General Management certification from INSEAD in France. Additionally, Acadia has promoted Holly Valdiviez to Senior Vice President of the Neuropsychiatric Franchise. In her expanded role, she will continue leading the sales and marketing efforts for NUPLAZID and report directly to Mr. Garner.

Thomas Andrew Garner expressed his excitement stating, “I am honoured to join Acadia in a commercial leadership role that aligns seamlessly with my experience. Acadia has two exceptional franchises in NUPLAZID® and DAYBUE, both with significant growth potential, as well as an impressive pipeline that has strong commercial potential. I am particularly enthusiastic about the opportunity to launch and grow our innovative therapies in rare diseases and CNS in the coming years.”